当前蛋白身份:P30274 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1VIN BOVINE CYCLIN A3 提交 1996-03-15 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 146–405(260 aa)
突变:S171G, DEL(1-170) 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.00 Å R-free 0.299
2G9X Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271 提交 2006-03-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 146–406(261 aa)
未记录 NU5 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, Hepes, VAPOR DIFFUSION, HANGING DROP, temperature 277K, pH 7.00
分辨率 2.50 Å R-free 0.265
2G9X Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271 提交 2006-03-07 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 146–406(261 aa)
未记录 NU5 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, Hepes, VAPOR DIFFUSION, HANGING DROP, temperature 277K, pH 7.00
分辨率 2.50 Å R-free 0.265
3BHT Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3 提交 2007-11-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:UNP residues 169-430
未记录 MFR 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine × 1 MG MAGNESIUM ION × 1 SGM MONOTHIOGLYCEROL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.00 Å R-free 0.220
3BHT Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 3 提交 2007-11-29 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:UNP residues 169-430
未记录 MFR 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine × 1 MG MAGNESIUM ION × 1 SGM MONOTHIOGLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.00 Å R-free 0.220
3BHU Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5 提交 2007-11-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:UNP residues 169-430
未记录 MHR 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.30 Å R-free 0.240
3BHU Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor meriolin 5 提交 2007-11-29 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:UNP residues 169-430
未记录 MHR 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.30 Å R-free 0.240
3BHV Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B 提交 2007-11-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:UNP residues 169-430
未记录 VAR 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol × 1 MG MAGNESIUM ION × 1 SGM MONOTHIOGLYCEROL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.10 Å R-free 0.229
3BHV Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor variolin B 提交 2007-11-29 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:UNP residues 169-430
未记录 VAR 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol × 1 MG MAGNESIUM ION × 1 SGM MONOTHIOGLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.10 Å R-free 0.229
3DDP Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8 提交 2008-06-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:UNP residues 169-430
未记录 RC8 (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, Hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.70 Å R-free 0.270
3DDP Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8 提交 2008-06-06 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:UNP residues 169-430
未记录 RC8 (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, Hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.70 Å R-free 0.270
3DDQ Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine 提交 2008-06-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:UNP residues 169-430
未记录 RRC R-ROSCOVITINE × 1 SGM MONOTHIOGLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, Hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 1.80 Å R-free 0.229
3DDQ Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor roscovitine 提交 2008-06-06 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:UNP residues 169-430
未记录 RRC R-ROSCOVITINE × 1 SGM MONOTHIOGLYCEROL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, Hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 1.80 Å R-free 0.229
3DOG Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1 提交 2008-07-04 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:UNP residues 169-430
未记录 NNN (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol × 1 SGM MONOTHIOGLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.70 Å R-free 0.248
3DOG Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor N-&-N1 提交 2008-07-04 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:UNP residues 169-430
未记录 NNN (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol × 1 SGM MONOTHIOGLYCEROL × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;ammonium sulphate, potassium chloride, HEPES pH7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.70 Å R-free 0.248
3MY5 CDk2/cyclinA in complex with DRB 提交 2010-05-09 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:UNP residues 169-430
未记录 RFZ 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole × 1 FMT FORMIC ACID × 3 SGM MONOTHIOGLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;1.1M Ammonium Sulphate, 100mM Hepes pH 7.0, 5mM DTT, saturated DRB, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.10 Å R-free 0.219
3MY5 CDk2/cyclinA in complex with DRB 提交 2010-05-09 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:UNP residues 169-430
未记录 RFZ 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole × 1 SGM MONOTHIOGLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;1.1M Ammonium Sulphate, 100mM Hepes pH 7.0, 5mM DTT, saturated DRB, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.10 Å R-free 0.219
3TNW Structure of CDK2/cyclin A in complex with CAN508 提交 2011-09-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa) 片段:cyclin boxes, UNP resdiues 169-430
未记录 F18 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;1.1 M ammonium sulphate, 100 mM HEPES, 5 mM DTT, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.00 Å R-free 0.227
3TNW Structure of CDK2/cyclin A in complex with CAN508 提交 2011-09-02 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:cyclin boxes, UNP resdiues 169-430
未记录 F18 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL × 1 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;1.1 M ammonium sulphate, 100 mM HEPES, 5 mM DTT, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 2.00 Å R-free 0.227
4BCO Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 提交 2012-10-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa)
未记录 T6Q 2-[[3-(4-ethanoyl-1,4-diazepan-1-yl)phenyl]amino]-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidine-5-carbonitrile × 1 SGM MONOTHIOGLYCEROL × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;COCRYSTALS WERE GROWN IN 1-1.25M AMMONIUM SULFATE, 0.5-0.9M KCL, 100MM HEPES, PH 7.0, 5MM DTT AND IN THE PRESENCE OF COMPOUND.
分辨率 2.05 Å R-free 0.226
4BCO Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 提交 2012-10-02 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa)
未记录 T6Q 2-[[3-(4-ethanoyl-1,4-diazepan-1-yl)phenyl]amino]-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidine-5-carbonitrile × 1 SGM MONOTHIOGLYCEROL × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;COCRYSTALS WERE GROWN IN 1-1.25M AMMONIUM SULFATE, 0.5-0.9M KCL, 100MM HEPES, PH 7.0, 5MM DTT AND IN THE PRESENCE OF COMPOUND.
分辨率 2.05 Å R-free 0.226
4BCQ Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 提交 2012-10-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa) 片段:RESIDUES 169-429
未记录 TJF 4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]-2-{[3-(morpholin-4-ylcarbonyl)phenyl]amino}pyrimidine-5-carbonitrile × 1 X-RAY DIFFRACTION
X-ray结晶条件 COCRYSTALS WERE GROWN IN 1-1.25M AMMONIUM SULFATE, 0.5-0.9M KCL, 100MM HEPES, PH 7.0, 5MM DTT AND IN THE PRESENCE OF COMPOUND.
分辨率 2.40 Å R-free 0.252
4BCQ Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor 提交 2012-10-02 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–429(261 aa) 片段:RESIDUES 169-429
未记录 TJF 4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]-2-{[3-(morpholin-4-ylcarbonyl)phenyl]amino}pyrimidine-5-carbonitrile × 1 X-RAY DIFFRACTION
X-ray结晶条件 COCRYSTALS WERE GROWN IN 1-1.25M AMMONIUM SULFATE, 0.5-0.9M KCL, 100MM HEPES, PH 7.0, 5MM DTT AND IN THE PRESENCE OF COMPOUND.
分辨率 2.40 Å R-free 0.252
6GUB CDK2/CyclinA in complex with Flavopiridol 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 F9Z 2-(2-chlorophenyl)-8-[(3~{R},4~{R})-1-methyl-3-oxidanyl-piperidin-4-yl]-5,7-bis(oxidanyl)chromen-4-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 2.52 Å R-free 0.238
6GUB CDK2/CyclinA in complex with Flavopiridol 提交 2018-06-19 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 F9Z 2-(2-chlorophenyl)-8-[(3~{R},4~{R})-1-methyl-3-oxidanyl-piperidin-4-yl]-5,7-bis(oxidanyl)chromen-4-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 2.52 Å R-free 0.238
6GUC CDK2/CyclinA in complex with SU9516 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 SU9 (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 2.00 Å R-free 0.223
6GUC CDK2/CyclinA in complex with SU9516 提交 2018-06-19 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 SU9 (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 2.00 Å R-free 0.223
6GUE CDK2/CyclinA in complex with AZD5438 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 169–430(262 aa)
未记录 FB8 4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-~{N}-(4-methylsulfonylphenyl)pyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 1.99 Å R-free 0.234
6GUE CDK2/CyclinA in complex with AZD5438 提交 2018-06-19 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 169–430(262 aa)
未记录 FB8 4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-~{N}-(4-methylsulfonylphenyl)pyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 1.99 Å R-free 0.234
6GUF CDK2/CyclinA in complex with CGP74514A 提交 2018-06-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 23D N2-[(1R,2S)-2-AMINOCYCLOHEXYL]-N6-(3-CHLOROPHENYL)-9-ETHYL-9H-PURINE-2,6-DIAMINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 2.65 Å R-free 0.255
6GUF CDK2/CyclinA in complex with CGP74514A 提交 2018-06-19 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 23D N2-[(1R,2S)-2-AMINOCYCLOHEXYL]-N6-(3-CHLOROPHENYL)-9-ETHYL-9H-PURINE-2,6-DIAMINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor
分辨率 2.65 Å R-free 0.255
8ROZ Cryo-EM structure of CDK2-cyclin A in complex with CDC25A 提交 2024-01-12 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 B 170–430(261 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4;50 mM HEPES, 200 mM NaCl, 1 mM DTT, pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.70 Å
9ESJ CDK2-cyclin A in complex with FragLite 31 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 HHT 2-(4-bromanyl-2-methoxy-phenyl)ethanoic acid × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.37 Å R-free 0.223
9ESJ CDK2-cyclin A in complex with FragLite 31 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 HHT 2-(4-bromanyl-2-methoxy-phenyl)ethanoic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.37 Å R-free 0.223
9ESK CDK2-cyclin A in complex with FragLite 30 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 W3D (4-bromo-2-oxopyridin-1(2H)-yl)acetic acid × 5 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.217
9ESK CDK2-cyclin A in complex with FragLite 30 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 W3D (4-bromo-2-oxopyridin-1(2H)-yl)acetic acid × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.217
9ESL CDK2-cyclin A in complex with FragLite 29 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 V3U 4-bromanyl-1-(2-methoxyethyl)pyridin-2-one × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.220
9ESL CDK2-cyclin A in complex with FragLite 29 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 V3U 4-bromanyl-1-(2-methoxyethyl)pyridin-2-one × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.220
9ESN CDK2-cyclin A in complex with FragLite 28 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 UUS 4-bromo-1-(2-hydroxyethyl)pyridin-2(1H)-one × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.213
9ESN CDK2-cyclin A in complex with FragLite 28 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 UUS 4-bromo-1-(2-hydroxyethyl)pyridin-2(1H)-one × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.213
9ESO CDK2-cyclin A in complex with FragLite 27 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 W3A (4-bromo-1H-pyrazol-1-yl)acetic acid × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.221
9ESO CDK2-cyclin A in complex with FragLite 27 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 W3A (4-bromo-1H-pyrazol-1-yl)acetic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.221
9ESP CDK2-cyclin A in complex with FragLite 26 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 UUV 4-bromo-1-(2-methoxyethyl)-1H-pyrazole × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.38 Å R-free 0.212
9ESP CDK2-cyclin A in complex with FragLite 26 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 UUV 4-bromo-1-(2-methoxyethyl)-1H-pyrazole × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.38 Å R-free 0.212
9ESQ CDK2-cyclin A in complex with FragLite 24 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 IT4 4-bromanyl-2-oxidanyl-benzoic acid × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.38 Å R-free 0.210
9ESQ CDK2-cyclin A in complex with FragLite 24 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 IT4 4-bromanyl-2-oxidanyl-benzoic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.38 Å R-free 0.210
9ESR CDK2-cyclin A in complex with FragLite 23 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 UU1 2-(4-bromo-1H-pyrazol-1-yl)ethan-1-ol × 8 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.227
9ESR CDK2-cyclin A in complex with FragLite 23 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 UU1 2-(4-bromo-1H-pyrazol-1-yl)ethan-1-ol × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.227
9ESS CDK2-cyclin A in complex with FragLite 22 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 UUG (4-bromo-2-methoxyphenyl)methanol × 5 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.44 Å R-free 0.219
9ESS CDK2-cyclin A in complex with FragLite 22 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 UUG (4-bromo-2-methoxyphenyl)methanol × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.44 Å R-free 0.219
9ESU CDK2-cyclin A in complex with FragLite 20 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 IJU 4-bromanyl-2-(methoxymethyl)pyridine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.216
9ESU CDK2-cyclin A in complex with FragLite 20 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 IJU 4-bromanyl-2-(methoxymethyl)pyridine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.216
9ESV CDK2-cyclin A in complex with FragLite 19 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 3Z7 4-bromo-2-methoxyphenol × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.229
9ESV CDK2-cyclin A in complex with FragLite 19 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 3Z7 4-bromo-2-methoxyphenol × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.40 Å R-free 0.229
9ESW CDK2-cyclin A in complex with FragLite 18 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 IJF (4-bromanylpyridin-2-yl)methanol × 7 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.38 Å R-free 0.239
9ESW CDK2-cyclin A in complex with FragLite 18 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 IJF (4-bromanylpyridin-2-yl)methanol × 5 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.38 Å R-free 0.239
9ESX CDK2-cyclin A in complex with FragLite 17 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 A1H6Y 1-bromanyl-4-methylsulfonyl-benzene × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.37 Å R-free 0.229
9ESX CDK2-cyclin A in complex with FragLite 17 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 A1H6Y 1-bromanyl-4-methylsulfonyl-benzene × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.37 Å R-free 0.229
9ESY CDK2-cyclin A in complex with FragLite 16 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 HH8 4-bromanyl-1,8-naphthyridine × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.262
9ESY CDK2-cyclin A in complex with FragLite 16 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 HH8 4-bromanyl-1,8-naphthyridine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.262
9ESZ CDK2-cyclin A in complex with FragLite 14 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 HGW 5-iodanylpyrimidine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.42 Å R-free 0.213
9ESZ CDK2-cyclin A in complex with FragLite 14 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 HGW 5-iodanylpyrimidine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.42 Å R-free 0.213
9ET0 CDK2-cyclin A in complex with FragLite 13 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 HHN 5-bromanylpyrimidine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.24 Å R-free 0.239
9ET0 CDK2-cyclin A in complex with FragLite 13 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 HHN 5-bromanylpyrimidine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.24 Å R-free 0.239
9ET1 CDK2-cyclin A in complex with FragLite 12 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 IJL 4-iodanylbenzamide × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.228
9ET1 CDK2-cyclin A in complex with FragLite 12 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 IJL 4-iodanylbenzamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.39 Å R-free 0.228
9ET2 CDK2-cyclin A in complex with FragLite 11 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 IJX ~{N}-(4-bromophenyl)ethanamide × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.37 Å R-free 0.231
9ET2 CDK2-cyclin A in complex with FragLite 11 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 IJX ~{N}-(4-bromophenyl)ethanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.37 Å R-free 0.231
9ET3 CDK2-cyclin A in complex with FragLite 10 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 1P8 6-bromo-1,3-dihydro-2H-indol-2-one × 6 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.34 Å R-free 0.221
9ET3 CDK2-cyclin A in complex with FragLite 10 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 1P8 6-bromo-1,3-dihydro-2H-indol-2-one × 8 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.34 Å R-free 0.221
9ET4 CDK2-cyclin A in complex with FragLite 9 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 A1H6X 4-iodanylbenzenesulfonamide × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.64 Å R-free 0.222
9ET4 CDK2-cyclin A in complex with FragLite 9 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 A1H6X 4-iodanylbenzenesulfonamide × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.64 Å R-free 0.222
9ET5 CDK2-cyclin A in complex with FragLite 8 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 T5G 4-bromobenzene-1-sulfonamide × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.53 Å R-free 0.221
9ET5 CDK2-cyclin A in complex with FragLite 8 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 T5G 4-bromobenzene-1-sulfonamide × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.53 Å R-free 0.221
9ET6 CDK2-cyclin A in complex with FragLite 7 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 HHQ 4-iodanyl-3~{H}-pyridin-2-one × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.55 Å R-free 0.239
9ET6 CDK2-cyclin A in complex with FragLite 7 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 HHQ 4-iodanyl-3~{H}-pyridin-2-one × 7 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.55 Å R-free 0.239
9ET7 CDK2-cyclin A in complex with FragLite 6 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 HGQ 4-bromanyl-1~{H}-pyridin-2-one × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.31 Å R-free 0.271
9ET7 CDK2-cyclin A in complex with FragLite 6 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 HGQ 4-bromanyl-1~{H}-pyridin-2-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.31 Å R-free 0.271
9ET8 CDK2-cyclin A in complex with FragLite 5 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 IIS 4-iodanylpyridin-2-amine × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.31 Å R-free 0.242
9ET8 CDK2-cyclin A in complex with FragLite 5 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 IIS 4-iodanylpyridin-2-amine × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.31 Å R-free 0.242
9ET9 CDK2-cyclin A in complex with FragLite 4 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 HEW 4-bromanylpyridin-2-amine × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.49 Å R-free 0.246
9ET9 CDK2-cyclin A in complex with FragLite 4 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 HEW 4-bromanylpyridin-2-amine × 7 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.49 Å R-free 0.246
9ETA CDK2-cyclin A in complex with FragLite 3 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 7ZX 4-bromanyl-1,2-oxazole × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.51 Å R-free 0.240
9ETA CDK2-cyclin A in complex with FragLite 3 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 7ZX 4-bromanyl-1,2-oxazole × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.51 Å R-free 0.240
9ETB CDK2-cyclin A in complex with FragLite 2 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 PYZ 4-IODOPYRAZOLE × 4 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.76 Å R-free 0.228
9ETB CDK2-cyclin A in complex with FragLite 2 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 PYZ 4-IODOPYRAZOLE × 8 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.76 Å R-free 0.228
9ETP CDK2-cyclin A in complex with FragLite 1 提交 2024-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 170–430(261 aa)
未记录 BYZ 4-bromo-1H-pyrazole × 8 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.48 Å R-free 0.231
9ETP CDK2-cyclin A in complex with FragLite 1 提交 2024-03-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 170–430(261 aa)
未记录 BYZ 4-bromo-1H-pyrazole × 5 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;Protein at 10 mg/ml. 0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES pH 7.0
分辨率 2.48 Å R-free 0.231